Old Web
English
Sign In
Acemap
>
authorDetail
>
Peter Kufer
Peter Kufer
University of Würzburg
Immunology
Medicine
Blinatumomab
Leukopenia
Immunotherapy
3
Papers
36
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Treatment with Anti-CD19 BiTE Antibody Blinatumomab (MT103 / MEDI-538) Is Able to Eliminate Minimal Residual Disease (MRD) in Patients with B-Precursor Acute Lymphoblastic Leukemia (ALL): First Results of An Ongoing Phase II Study.
2008
Blood
Max S. Topp
Nikola Goekbuget
Peter Kufer
Gerhard Zugmaier
Evelyn Degenhard
Svenja Neumann
Heinz A Horst
A. Viardot
Mathias Schmid
Oliver G. Ottmann
Margit Schmidt
Carsten Reinhardt
Patrick A Baeuerle
Dirk Nagorsen
Dieter Hoelzer
Ralf Bargou
Show All
Source
Cite
Save
Citations (25)
Sustained Response Duration Seen after Treatment with Single Agent Blinatumomab (MT103/MEDI-538) in the Ongoing Phase I Study MT103- 104 in Patients with Relapsed NHL
2008
Blood
Ralf Bargou
Peter Kufer
Mariele Goebeler
Stefan Knop
Hermann Einsele
Richard Noppeney
A. Viardot
Patrick A Baeuerle
Carsten Reinhardt
Margit Schmidt
Petra Klappers
Dirk Nagorsen
Gerhard Zugmaier
Show All
Source
Cite
Save
Citations (8)
The Bi-Specific T-Cell Enhancer (BiTE) MT103 (MEDI-538) Induces Clinical Responses in Heavily Pre-Treated NHL Patients: Update from the Ongoing Phase I Study MT103-104.
2006
Blood
Ralf C. Bargou
Richard Noppeney
Martin Schuler
Georg Hess
Ch Gerecke
Florian Zettl
J. Birkmann
A. Viardot
Petra Kirchinger
Patrick A. Baeuerle
Carsten Reinhardt
Matthias Klinger
Martin Libicher
Mariele Goebeler
Herrmann Einsele
Peter Kufer
Gerhard Zugmaier
Eugen Leo
Show All
Source
Cite
Save
Citations (3)
1